On April 26 2023, ERA4TB had it’s mid-term review by its funder, the Innovative Health Initiative (formerly the Innovative Medicine’s Initiative’).
Bringing together key project members, IHI’s Scientific Officer and three external reviewers, the review assessed the progress of the project against its objectives and milestones. The reviewers also provided feedback and recommendations for future improvement.
ERA4TB was described by reviewers as ‘a very ambitious, well organized and impressive program addressing a major health issue’ the reviewers went on to praise the ‘clearly organized consortium, of extremely competent and highly complementary established groups in their respective fields of expertise’ and the ‘impressive scope of original molecules’.
Amongst the recommendations for the future, ERA4TB was encouraged to further explore its work around developing combinations, continue to seek new assets to add to the pipeline, and increase engagement with complementary initiatives and patient representatives.
Work has already begun within the project to address these and other recommendations.
